Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SC Daratumumab in Healthy Participants
NCT03320707Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple myeloma (MM) comparing Daratumumab with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at Day 141 and Serious Adverse Events at Day 141. Started Oct 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03320707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320707.